Brain kinetics of methylphenidate (Ritalin) enantiomers after oral administration

  title={Brain kinetics of methylphenidate (Ritalin) enantiomers after oral administration},
  author={Y. Ding and S. Gatley and P. Thanos and C. Shea and V. Garza and Youwen Xu and P. Carter and P. King and D. Warner and Nicholas B Taintor and D. J. Park and B. Pyatt and J. Fowler and N. Volkow},
Methylphenidate (MP) (Ritalin) is widely used for the treatment of attention deficit hyperactivity disorder (ADHD). It is a chiral drug, marketed as the racemic mixture of d‐ and l‐threo enantiomers. Our previous studies (PET and microdialysis) in humans, baboons, and rats confirm the notion that pharmacological specificity of MP resides predominantly in the d‐isomer. A recent report that intraperitoneally (i.p.) administered l‐threo‐MP displayed potent, dose‐dependent inhibition of cocaine‐ or… Expand
50 Citations
Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter?
  • 57
Plasma and brain concentrations of oral therapeutic doses of methylphenidate and their impact on brain monoamine content in mice
  • 47
  • Highly Influenced
New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder
  • 48
A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study.
  • 87
  • Highly Influenced
  • PDF
Pharmacokinetics, dose‐range, and mutagenicity studies of methylphenidate hydrochloride in B6C3F1 mice
  • 33
A pharmacokinetic model of oral methylphenidate in the rat and effects on behavior
  • 27
Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder
  • 6
Methylphenidate HCl: therapy for attention deficit hyperactivity disorder
  • 24


Enantioselective pharmacokinetics and pharmacodynamics of dl‐thero‐mcthylphenidate in children with attention deficit hyperactivity disorder
  • 120
  • Highly Influential
Comparison between intraperitoneal and oral methylphenidate administration: A microdialysis and locomotor activity study.
  • 244
Therapeutic Doses of Oral Methylphenidate Significantly Increase Extracellular Dopamine in the Human Brain
  • 681
  • PDF
Pharmacokinetics and in vivo specificity of [LLC]dl‐threo‐methylphenidate for the presynaptic dopaminergic neuron
  • 70
Distribution of methylphenidate and p-hydroxymethylphenidate in rats.
  • 50
Enantioselective Pharmacokinetics of dl-threo-Methylphenidate in Humans
  • 77
Stereoselective urinary pharmacokinetics of dl-threo-methylphenidate and its major metabolite in humans.
  • 22
  • Highly Influential
Evidence that dogs do not model enantioselective pharmacokinetics of dl-methylphenidate in humans.
  • 15
Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and l-threo-methylphenidate in the human and baboon brain
  • 137
  • PDF
Pharmacology of the enantiomers of threo-methylphenidate.
  • 185